A809 1.3% was observed (p< 0.001). For VAS-identified adherent patients, CVR decreased significantly by 4.4% from baseline to 90 days (p< 0.001). However, a significant decrease of 4.3% (p< 0.001) was also observed for VAS-identified non-adherent patients. ConClusions: Patients identified as adherent using the first item of the BAAS showed significantly improved 10-year cardiovascular risk scores after 90 days of treatment with valsartan, compared to patients who were identified as non-adherent. The VAS scale was not sufficiently sensitive to determine the effect of adherence on cardiovascular risk score.